Neoadjuvent androgen deprivation for seminal vesicle reduction: The optimal portion of seminal vesicle included in the high-dose CTV in localized prostate cancer radiotherapy

To clarify the length and volume reduction of seminal vesicles (SVs) after neo-adjuvant hormonal therapy (NHT), in order to help contour optimal SV included into high-dose clinical target (CTV) for radiotherapy intermediate- high-risk patients. MR images both before NHT (5.3 ​± ​2.2 months) were collected from thirty-one patients with cT2-4N0M0 prostate cancer. was measured axial T1WI, while obtained a reconstructed oblique coronary plane through its long 3D sequence. SVs showed evident (length: median 12.1%, range 4.0%–28.0%; volume: 39.9%, 9.4%–66.2%). For without detected involvement, shortening (16.7 ​4.8)% (11.1 ​4.4)% (P ​< ​0.001); involved lesions, (41.0 ​16.0)% (66.3 ​14.4)%, respectively ​0.001), indicating more sensitive response portion than normal SV. Both will be reduced receiving NHT. Besides, invaded segments shrink tissue, that within CTV can reduced.